About this episode
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.
In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed 'molecular gates.' His company, Gate, is working to exploit a previously uncharted avenue in cell biology—the secretory translocon—for therapeutic intervention. This approach has the potential to combat diseases otherwise resistant to existing therapeutics.
Jordi also imparts valuable insights on the power of platform-based problem-solving and team building.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Raising Health publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Raising Health
Moderna CEO Stéphane Bancel on the Next Era of mRNA
Raising Health
Clinical AI Comes of Age | Suchi Saria on the Future of Healthcare
Raising Health
AI, Healthcare, and 700 Million Patients | Nicolas Abad, Telepatía
Raising Health
Healthcare Will Benefit Most from AI | Julie Yoo on StartUp Health
Raising Health